Strategies for enhanced drug delivery to the central nervous system

Indian Journal of Pharmaceutical Sciences

Volumn 70, Issue 2, 2008, Pages 145-153

  Dwibhashyam, V S N M ^b   Nagappa, A ^a  

^a KASTURBA HOSPITAL   (India)

^b TherDose Pharma Pvt Ltd   (India)

Author keywords

Blood brain barrier; CNS drug delivery; Nano particles; P glycoprotein

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BIRICODAR; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOSPORIN A; DIGOXIN; DOXORUBICIN; DRUG CARRIER; EPIPODOPHYLLOTOXIN DERIVATIVE; FLOXURIDINE; GLYCOPROTEIN P; INTERLEUKIN 2; LAMIVUDINE; LOPERAMIDE; METHOTREXATE; MORPHINE; NANOPARTICLE; PROTEINASE INHIBITOR; SOMATOMEDIN C; STEROID HORMONE; TUBOCURARINE CHLORIDE; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VINCA ALKALOID; ZIDOVUDINE;

BIOTECHNOLOGY; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TISSUE LEVEL; HUMAN; HYDROPHOBICITY; LIPOPHILICITY; REVIEW;

EID: 46349098694     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.41446     Document Type: Review

References (70)

1. Martin B, Robert L, Henry B, Mathiowitz E. Encyclopedia of controlled drug delivery, Vol. 1, New York: John Wiley and Sons Inc; 1999. p. 184-210.
2. Pardridge WM. Recent advances in blood-brain barrier transport. Annu Rev Pharmacol Toxicol 1988;28:25-39.
3. Tamargo RJ, Brem H. Transporting therapeutics across the blood-brain barrier. Neurosurg 1992;2:259-79.
4. Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol Med Today 1996;3:106-13.
5. Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, et al. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly (butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett 2002;126:131-41.
6. Pankajavalli R. The Role of P-glycoprotein in the Blood-Brain Barrier. Einstein Quart J Biol Med 2003;19:160-5.
7. Dwibhashyam VS, Vijayaratna J. The Permeability Glycoprotein (P-gp): A Threat to Effective Drug Therapy? Indian Drugs 2006;43:609-18.
8. Tsuji A, Tamai I. Blood-brain barrier function of P-glycoprotein. Adv Drug Deliv Rev 1997;25:287-98.
9. Masereeuw R, Jaehde UM, Langemeijer W, DeBoer AG, Breimer DD. In vitro and in vivo transport of zidovudine (AZT) across the blood brain barrier and the effect of transport inhibitors. Pharm Res 1994;11:324-30.
10. Varma, MV, Yasvanth A, Chinmoy SD, Ramesh P. P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacol Res 2003;48:347-59.
11. Bhagvant D, Joseph PYK, James PE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002;16:237-8.
12. Yu-li Lo. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J Control Release 2003;90:37-48.
13. Madrid Y, Langer LF, Brem H, Langer R. New directions in the delivery of drugs and other substances to the central nervous system. Adv Pharmacol 1991;22:299-324.
14. Bodor N, Buchwald P. Drug targeting via retrometabolic approaches. Pharmacol Therp 1997;76:1-27.
15. Bodor N, Farag HH, Brewster ME. Site-specific, sustained release of drugs to the brain. Science 1981;214:1370-2.
16. Omar FA, Farag HH, Bodor N. Synthesis and evaluation of a redox chemical delivery system for brain-enhanced dopamine-containing an activated carbamate-type ester. J Drug Target 1994;2:309-16.
17. Bodor N. A strategy for delivering peptides into the central nervous system by sequential metabolism. Science 1992;257:1698-700.
18. Prokai L. Chemical delivery system to transport a pyroglutamyl peptide amide to the central nervous system. J Am Chem Soc 1994;116:2643-44.
19. Prokai K, Tatrai PL, Bodor N. Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design. J Med chem 1996;39:4775.
20. Brownlees J, Williams CH. Peptidases peptides and the mammalian blood-brain barrier. J Neurochem 1993;60:793.
21. Greig NH. Optimizing drug delivery to brain tumors. Cancer Treat Rev 1987;14:1-28.
22. Scheld WM. Drug delivery to the central nervous system: General principles and relevance to therapy for infections of the central nervous system. Rev Infect Dis 1989;2:1669-90.
23. Bickel U, Yoshikawa T, Pardridge WM. Pharmacokinetics and saturable blood-brain barrier transport of biotin bound to a conjugate of avidin and a monoclonal antibody to the transferrin receptor. Adv Drug Del Rev 1993;10:205-45.
24. Kumagai AK, Eisenberg J, Pardridge WM. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries: Model system of blood-brain barrier transport. J Biol chem 1987;262:15214-9.
25. Pardridge WM, Triguero D, Buciak JL. Beta-endorphin chimeric peptides: Transport through the blood-brain barrier in vivo and cleavage of disulfide linkage by brain. J Endocrinol 1990;126:977-84.
26. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature 1984;3:162-3.
27. Yoshikawa T, Pardridge WM. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J Pharmacol Exp Ther 1992;263:897-903.
28. Friden PM, Walus LR, Watson P, Doctrow SR, Kozarich JW, Backman C, et al. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 1993;259:373-7.
29. Pardridge WM, Boado RJ, Kang YS. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci USA 1995;92:5592-6.
30. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996;93:14164-9.
31. Lindgren M, Hallbrink M, Prochiantz A, Langel U. Cell penetrating peptides. Trends Pharmacol Sci 2000;21:99-103.
32. Misra A, Jain NK. Progress in controlled and novel drug delivery systems, 1st ed. New Delhi: CBS Publishers and Distributors; 2004. p. 23-47.
33. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanor AA. Passage of peptides through the blood- brain barrier with colloidal polymer particles nanoparticles. Brain Res 1995;674:171-4.
34. Kreuter J. Nanoparticlate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65-81.
35. Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. Curr Med Chem 2002;2:241-9.
36. Zordan-Nudo T, Ling, Liv Z, Georges E. Effect of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res 1993;53:5994-6000.
37. Luca C, Francesca G, Giovanni T, Francesco R, Vandelli MA, Flavio F. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Release 2005;108:84-96.
38. Yung-Chih K, Hung-Hao C. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Pharm Nanotechnol 2006;327:160-9.
39. Gulati A, Nath C, Shanker K, Srimal, RC, Dhawan KN, Bhargava KP. Effect of alcohols on the permeability of blood-brain barrier. Pharmacol Res Commun 1985;1:85-93.
40. st Super Sanita 1990;26:39-42.
41. Mayordomo F, Renau-Piqueras J, Megias L, Guerri C, Iborra FJ, Azorin I, et al. Cytochemical and stereological analysis of rat cortical astrocytes during development in primary culture: Effect of prenatal exposure to ethanol. Int J Dev Biol 1992;36:311-21.
42. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means. Neurosurgery 1998;42:1083-99.
43. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Fiamengo SA, Neuwelt EA. Improving drug delivery to intra cerebral tumor and surrounding brain in a rodent model: A comparison of osmotic versus Bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery 1998;43:879-86.
44. Bullard DE, Bigner SH, Bigner DD. Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. Cancer Res 1985;45:5240-5.
45. Inamura T, Nomura T, Bartus RT, Black KL. Intracarotid infusion of RMP-7, a bradykinin analog: A method for drug delivery to brain tumors. J Neurosurg 1994;81:752-8.
46. Chio CC, Baba T, Black KL. Selective blood-tumor barrier disruption by leukotrienes. J Neurosurg 1992;77:407-10.
47. Shivers RR, Wijsman JA. Blood-brain barrier permeability during hyperthermia. Prog Brain Res 1998;115:413-24.
48. Cho C W, Lin Y, Cobb WN. Ultrasound-induced mild hyperthermia as a novel approach to increase drug uptake in brain micro vessel endothelial cells. Pharm Res 2002;115:413-24.
49. Thorne RG, Frey WH. Delivery of neurotrophic factors into the central nervous system. Clin Pharmacokinet 2001;40:907-46.
50. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000;11:1-18.
51. Mathison S, Nagilla R, Bhaskar KU. Nasal route for direct delivery of solutes to the central nervous system: Fact or fiction? J Drug Target 1998;5:415- 41.
52. Thorne RG, Emory CR, Ala TA, Frey WH. Brain, Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 1995;692:278-82.
53. Balin BJ, Broadwell RD, Salcman M, El-Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. Comp Neurol 1986;251:260-80.
54. Baker H, Spencer RF. Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp Brain Res 1986;63:461-73.
55. Broadwell RD, Balin BJ. Endocytic and exocytic pathways of the neuronal secretory process and trans-synaptic transfer of wheat germ agglutinin- horseradish peroxidase in vivo. J Comp Neurol 1985;242:632-50.
56. Shipley MT. Transport of molecules from nose to brain. Brain Res Bull 1985;15:129-42.
57. Kida S, Pantazis A, Weller RO. CSF drains directly from the sub arachnoid space into nasal lymphatics in the rat -Anatomy, histology and immunological significance. Neuropathol Appl Neurobiol 1993;19:480-8.
58. Foldi M. The brain and the lymphatic system. Lymphol 1996;29:1-9.
59. Feron VJ, Arts JH, Kuper CF, Slootweg PJ, Woutersen RA. Health risks associated with inhaled nasal toxicants. Crit Rev Toxicol 2001;31:313-47.
60. Sakane T, Akizuki M, Yamashita S, Sezaki H, Nadai T. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: The relation to the dissociation of the drug. J Pharm Pharmacol 1994;46:378-9.
61. Sakane T, Akizuki M, Taki Y, Yamashita S, Sezaki H, Nadai T. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: The relation to the molecular weight of drugs. J Pharm Pharmacol 1995;47:379-81.
62. Harbaugh RE, Saunders RL, Reedert RF. Use of implantable pumps for central nervous system drug infusions to treat neurological disease. Neurosurgery 1988;23:693-8.
63. Sladek J, Gash D. Nerve-cell grafting in Parkinson's disease. J Neurosurg 1988;68:337-51.
64. Snyder EY, Senut MC. The use of non neuronal cells for gene delivery. Nerobiol Dis 1997;4:69-102.
65. Yurek DM, Sladek JR. Dopamine cell replacement: Parkinson.s disease. Annu Rev Neurosci 1990;13:415-40.
66. Cohen KA, Liu T, Bissonette R, Puri RK, Frankel AE. DAB389EGF fusion protein therapy of refractory Glioblastoma Multiforme. Curr Pharm Biotechnol 2003;4:39-49.
67. Asoh S, Ohsawa I, Mori T, Katsura K, Hiraide T, Katayama Y, et al. Protection against ischemic brain injury by protein therapeutics. Proc Natl Acad Sci USA 2002;99:17107-12.
68. Alexi T, Venero JL, Hefti F. Protective effects of neurotrophin-4/5 and transforming growth factor-alpha on striatal neuronal phenotypic degeneration after excitotoxic lesioning with quinolinic acid. Neuroscience 1997;78:73-86.
69. Susan A. Biotechnology, brain and future. Trends Biotechnol 2005;23:34-41.
70. Banks WA. Oligonucleotides targeting prion diseases. J Pharmacol Exp Ther 2001;3:1113-21.